Abstracts tagged "Employment and Work Disability"

Abstract Number: 3056 • 2016 ACR/ARHP Annual Meeting
Efficacy of a Work Disability Prevention Program for People with Rheumatic and Musculoskeletal Conditions: A Randomized Controlled Trial
Julie J. Keysor^1,2, Michael P. LaValley³, Carrie Brown⁴, David T. Felson⁵, Rawan AlHeresh⁶, Molly Vaughan⁷, Robert A. Yood⁸, John Reed⁹ and Saralynn Allaire¹⁰, ¹Physical Therapy, Boston University, Boston, MA, ²Clinical Epidemiology Research and Training, Boston University School of Medicine, Boston, MA, ³Biostatistics, Boston University School of Public Health, Boston, MA, ⁴Boston University School of Public Health, Boston, MA, ⁵Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁶Rheumatology, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia, ⁷635 Commonwealth Avenue, Room 651, Boston University College of Health & Rehabilitation Sciences, Boston, MA, ⁸Fallon Clinic, Worcester, MA, ⁹Rheumatology, Reliant Medical Group, Worcester, MA, ¹⁰Clinical Epidemiology Research and Training Unit, Clinical Epidemiology, BUSM, Boston, MA
Background/Purpose: Rheumatic and musculoskeletal conditions are leading causes of work disability. A previous trial showed a preventive work disability intervention delivered by vocational rehabilitation counselors…
Abstract Number: 449 • 2013 ACR/ARHP Annual Meeting
Work Instability In Early Rheumatoid Arthritis With Elevated Risk Of Employment Loss: Effects Of Adalimumab/Methotrexate Combination Therapy Versus Methotrexate In a Randomized Clinical Trial
Arthur Kavanaugh¹, Josef S. Smolen², Arijit Ganguli³, Hartmut Kupper³, Mary Cifaldi³, Naijun Chen³ and Dennis Revicki⁴, ¹University of California, San Diego, La Jolla, CA, ²Medical University of Vienna, Vienna, Austria, ³AbbVie Inc., North Chicago, IL, ⁴United BioSource, Bethesda, MD
Background/Purpose: Intensive treatment of early rheumatoid arthritis (RA) has been shown to reduce functional disability over time and to positively impact employment outcomes. Adalimumab (ADA)…